Effect of intraperitoneal PERIDAN™ concentrate adhesion reduction device on clinical findings, infection, and tissue healing in an adult horse jejunojejunostomy model.
OBJECTIVE
To evaluate the effect of PERIDAN™ Concentrate on clinical findings, infection, and tissue healing in adult horses undergoing celiotomy and jejunojejunostomy.


METHODS
Block randomized blinded experimental in vivo study.


METHODS
Adult horses (n = 12).


METHODS
Horses had jejunojejunostomy at 2 sites and were administered 5 L of diluted PERIDAN™ Concentrate (6 horses) or Lactated Ringer's Injection (LRS) control intraperitoneally (6 horses) before body wall closure. Postoperative monitoring comprised physical examinations, serial hematology, coagulation and chemistry panels, and ultrasonographic examination. Horses were euthanatized 10 days postoperatively. Anastomoses and linea alba incisions were tested for mechanical strength; and tissue healing, inflammation, and infection were assessed by histological evaluation. Data were analyzed using a mixed model ANOVA. Level of significance was P < .05.


RESULTS
No physical examination differences were observed between groups. Statistically significant differences were observed in leukocyte and neutrophil counts, prothrombin time, antithrombin III activity, intestinal bursting pressures, and histologic healing grade in the mid region of the linea alba. These differences were minimal, and of no observable clinical significance. Other blood variable and histologic differences between groups were not significant.


CONCLUSIONS
PERIDAN™ Concentrate was safely administered intraperitoneally to healthy horses undergoing celiotomy and anastomosis.
Department of Clinical Studies, New Bolton Center, University of Pennsylvania, Kennett Square, PA, USA. vetsam@gmail.com
Samantha
S
Morello
Louise L
LL
Southwood
Julie
J
Engiles
Joann
J
Slack
Aaron
A
Crack
Christopher M K
CM
Springate
D000818:Animals; D006736:Horses; D007582:Jejunostomy / Q000379:methods / Q000662:veterinary*; D007583:Jejunum / Q000473:pathology; D011134:Polysaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D013530:Surgical Wound Infection / Q000517:prevention & control / Q000662:veterinary*; D000267:Tissue Adhesions / Q000517:prevention & control / Q000662:veterinary*; D014945:Wound Healing
D011134:Polysaccharides; C007789:fucoidan